

Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus

Short Title: ID Delivery of a MERS DNA vaccine in NHPs

Authors: Ami Patel^{1†}, Emma L. Reuschel^{1†}, Ziyang Xu^{1,2}, Faraz I. Zaidi¹, Kevin Y. Kim¹, Dana P. Scott³, Janess Mendoza⁴, Stephanie Ramos⁴, Regina Stoltz¹, Friederike Feldmann³, Atsushi Okumura⁵, Kimberly Meade-White⁵, Elaine Haddock⁵, Tina Thomas³, Rebecca Rosenke³, Jamie Lovaglio³, Patrick W. Hanley³, Greg Saturday³, Kar Muthumani¹, Heinz Feldmann⁵, Laurent M. Humeau⁴, Kate E. Broderick⁴, David B. Weiner^{1*}

Affiliations:

¹Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA

²Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

³Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA


⁴Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USA

⁵Laboratory of Virology, Division of Intramural Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA

*Corresponding Author: David B Weiner, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, dweiner@wistar.org

†Authors contributed equally

1 **Supplementary Materials:**



2

3 **Supplemental Figure S1.** Total peptide stimulated antigen-specific IFN γ ELISPOT responses (Related to Fig. 1). The total peptide stimulated
4 IFN γ ELISPOT response for each animal is shown by the symbols with the group average indicated by the bar. Error bars are SEM. Open symbols
5 depict the responses for animals that were not selected for challenge.

6

7 **Table S1.** Description of clinical signs of disease from all animals post challenge (Clinical signs of disease: Green = normal, yellow = moderate,
 8 red = severe) (Related to Figure 2A).

| Group | Animal | Day 1-2 | Day 3-4 | Day 5-6 |
|---------|--------|--|---|--|
| IM | 7001 | Deep abdominal breathing | Deep abdominal breathing | Deep abdominal breathing |
| | 7045 | Normal | Normal | Normal |
| | 6839 | Increased abdominal breathing, severely decreased appetite | Increased abdominal breathing, severely decreased appetite | Increased abdominal breathing, severely decreased appetite |
| | 7032 | Normal | Normal | Normal |
| ID-high | 6827 | Normal | Normal | Normal |
| | 6848 | Decreased appetite | Decreased appetite | Normal |
| | 7037 | Normal | Normal | Normal |
| | 7024 | Normal | Normal | Normal |
| ID-low | 7005 | Normal | Normal | Normal |
| | 6880 | Normal | Normal | Decreased appetite |
| | 6824 | Decreased appetite | Decreased appetite | Decreased appetite |
| | 6997 | Normal | Normal | Normal |
| control | 7030 | Decreased appetite | Increased abdominal breathing, decreased appetite | Increased abdominal breathing, decreased appetite |
| | 6852 | Irregular increased respirations, decreased appetite | Irregular increased respirations, pale, decreased appetite | Irregular increased respirations, hunched posture, pale, decreased appetite |
| | 6831 | Increased irregular respirations | Increased irregular respirations | Increased irregular respirations, pilo erection |
| | 7014 | Increased abdominal breathing, decreased appetite | Hunched posture, increased abdominal breathing, decreased appetite | Hunched posture, increased abdominal breathing, severely decreased appetite |
| | 150129 | Increased abdominal irregular respirations, decreased appetite | Increased abdominal irregular respirations, hunched posture, decreased appetite | Increased abdominal irregular respirations, hunched posture, severely decreased appetite |
| | 6071 | Normal | Deep abdominal breathing, slower | Hunched posture, quiet, irregular breathing, decreased appetite |

9
 10
 11
 12
 13

14 **Table S2.** Summary of p values for lung viral loads between all vaccinated and control animals (corrected for multiple comparisons, $p < 0.05$ is
 15 considered significant. Blue = significant) (Related to Fig. 2B). Parametric t-test, adjusted for multiple comparisons using a Bonferroni
 16 correction, was used for statistical analysis.

| RLL | LLL | RML | LML | RUL | LUL | R. Bronchus | L. Bronchus |
|------------|------------|------------|------------|------------|------------|--------------------|--------------------|
| p=0.0061 | p=0.0020 | p<0.0001 | p=0.0002 | P=0.0225 | p<0.0001 | p<0.0001 | p=0.0514 |

18
 19
 20 **Table S3.** Summary of p values for lung viral loads between vaccine groups and control animals (corrected for multiple comparisons, $p < 0.05$ is
 21 considered significant. Blue = significant) (Related to Fig. 2C and 2D). Parametric t-test, adjusted for multiple comparisons using a Bonferroni
 22 correction, was used for statistical analysis.

| Group | RLL | LLL | RML | LML | RUL | LUL | R. Bronchus | L. Bronchus |
|--------------|------------|------------|------------|------------|------------|------------|--------------------|--------------------|
| IM | p=0.0061 | p=0.0249 | p=0.0002 | p=0.0026 | p=0.0118 | p<0.0001 | p<0.0001 | p=0.1706 |
| ID-high | p=0.0047 | p=0.0003 | p=0.0025 | p=0.0261 | p=0.1153 | p=0.0128 | p=0.0311 | p=0.7009 |
| ID-low | p=0.1615 | p<0.0001 | p=0.0064 | P<0.0001 | p=0.1552 | p=0.0098 | p=0.0017 | p=0.0243 |

25
 26